Longeveron (LGVN) Accounts Payables (2022 - 2026)
Longeveron's (LGVN) quarterly Accounts Payables came in at $293000.0 in Q1 2026, down 20.16% year-on-year from $367000.0 in Q1 2025, and down 30.73% quarter-over-quarter from $423000.0 in Q4 2025.
Longeveron (LGVN) Accounts Payables (2022 - 2026) Analysis & Trends
Longeveron's Accounts Payables history runs 5 years deep, the most recent figure standing at $293000.0 for Q1 2026.
- On a quarterly basis, Accounts Payables fell 20.16% year-over-year to $293000.0 in Q1 2026; TTM through Mar 2026 was $293000.0, a 20.16% decrease from a year earlier, with the FY2025 full-year figure at $423000.0, up 327.27% from the prior year.
- Accounts Payables fell to $293000.0 in Q1 2026 per LGVN's latest filing, from $423000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $1.8 million in Q4 2022 and bottomed at $99000.0 in Q4 2024.
- The 5-year median for Accounts Payables is $669000.0 (2023), against an average of $833750.0.
- Across the five-year window, Accounts Payables sank 84.48% in 2024 and soared 327.27% in 2025, its largest moves.
- Year by year, Accounts Payables stood at $1.8 million in 2022, then plunged by 63.56% to $638000.0 in 2023, then sank by 84.48% to $99000.0 in 2024, then surged by 327.27% to $423000.0 in 2025, then tumbled by 30.73% to $293000.0 in 2026.
- Per Business Quant, the three latest LGVN Accounts Payables figures stand at $293000.0 (Q1 2026), $423000.0 (Q4 2025), and $1.1 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 293,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 293,000.00 |
| Dec 31, 2025 | 423,000.00 |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 700,000.00 |
| Mar 31, 2025 | 367,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Sep 30, 2024 | 887,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 1.47 Mn |
| Dec 31, 2023 | 638,000.00 |
| Jun 30, 2023 | 1.70 Mn |
| Dec 31, 2022 | 1.75 Mn |